Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ZYDELIG vs BONTRIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Idelalisib is a selective inhibitor of phosphatidylinositol 3-kinase delta (PI3Kδ), blocking the PI3K/AKT signaling pathway, leading to reduced proliferation, survival, and migration of malignant B cells.
Bontril (phendimetrazine) is a sympathomimetic amine that acts as an appetite suppressant. Its mechanism involves stimulating the hypothalamus to release norepinephrine and dopamine, which reduces hunger cues. It is a prodrug that is metabolized to the active agent phenmetrazine, which inhibits reuptake and increases release of norepinephrine and dopamine in the central nervous system.
Relapsed chronic lymphocytic leukemia (CLL) in combination with rituximab,Relapsed follicular B-cell non-Hodgkin lymphoma (FL) in patients who have received at least two prior systemic therapies,Relapsed small lymphocytic lymphoma (SLL) in patients who have received at least two prior systemic therapies
FDA-approved for management of obesity as a short-term adjunct (few weeks) in a regimen of weight reduction based on caloric restriction, exercise, and behavior modification. Off-label uses are not well documented due to limited evidence.
150 mg orally twice daily, taken with food.
BONTRIL 50 mg orally once daily, with or without food.
Terminal elimination half-life is 6.5 hours (range 4-10 hours) after oral administration, supporting twice-daily dosing.
18-24 hours; prolonged in renal impairment (up to 40 hours) requiring dose adjustment.
Primarily metabolized by aldehyde oxidase (AO) and CYP3A4, with minor contributions from UGT1A4.
Phendimetrazine is extensively metabolized in the liver, primarily via N-demethylation to its active metabolite phenmetrazine. Minor pathways include hydroxylation and conjugation. Cytochrome P450 enzymes are involved, though specific isoforms are not fully characterized.
Primarily hepatic metabolism, with 44% of dose excreted in feces (as metabolites) and 22% in urine (unchanged drug and metabolites).
Primarily renal (60-70% unchanged) with minor biliary/fecal (10-15% as metabolites).
84% bound to plasma proteins, primarily to albumin and alpha-1-acid glycoprotein.
85-90% bound to albumin and alpha-1-acid glycoprotein.
Mean volume of distribution is 113 L (approximately 1.4 L/kg), indicating extensive tissue distribution.
3-5 L/kg; indicates extensive tissue distribution.
Absolute oral bioavailability is 40% (range 30-50%) due to first-pass metabolism.
Oral: 70-80% (first-pass metabolism); IV: 100%.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). For severe renal impairment (Cr Cl <30 m L/min), not recommended due to lack of data.
GFR >60 m L/min: no adjustment. GFR 30-60 m L/min: reduce dose to 25 mg once daily. GFR <30 m L/min: use is not recommended.
Child-Pugh Class A: No dose adjustment. Child-Pugh Class B: Reduce dose to 100 mg twice daily. Child-Pugh Class C: Not recommended.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose to 25 mg once daily. Child-Pugh Class C: use is contraindicated.
Safety and efficacy not established for patients <18 years.
Weight-based: 1 mg/kg orally once daily, with a maximum of 50 mg. Not recommended for children weighing less than 10 kg.
No specific dose adjustment recommended, but monitor for age-related renal and hepatic function changes.
Start at 25 mg orally once daily; may increase to 50 mg after 2 weeks if tolerated and renal function is adequate (Cr Cl >60 m L/min).
WARNING: FATAL AND SERIOUS TOXICITIES: Hepatic, severe diarrhea/colitis, pneumonitis, and intestinal perforation. Fatal and/or serious hepatotoxicity occurred in 18% of patients. Fatal and/or serious diarrhea or colitis occurred in 14%. Fatal and/or serious pneumonitis occurred in 4%. Fatal and/or serious intestinal perforation occurred in <1%.
None
Hepatotoxicity: Monitor liver function tests,Severe diarrhea/colitis: Manage with supportive care and corticosteroids,Pneumonitis: Interrupt therapy and evaluate,Intestinal perforation: Discontinue if suspected,Infections: Monitor for opportunistic infections, including CMV,Neutropenia: Monitor blood counts,Embryofetal toxicity: Can cause fetal harm,Vaccinations: Avoid live vaccines during treatment
Risk of abuse, dependence, and tolerance; monitor for signs of addiction.,May cause serious cardiovascular events including pulmonary hypertension and valvular heart disease, especially with long-term use.,May impair ability to drive or operate machinery due to dizziness or blurred vision.,Use with caution in patients with hypertension, hyperthyroidism, glaucoma, or history of drug abuse.,Concomitant use with other sympathomimetics or MAO inhibitors can cause hypertensive crisis.,Not recommended for use in patients with a history of epilepsy or those taking other anorectic agents.
History of severe hypersensitivity (e.g., anaphylaxis, Stevens-Johnson syndrome) to idelalisib or any excipient
Known hypersensitivity to phendimetrazine or any component of the formulation.,History of cardiovascular disease including coronary artery disease, arrhythmias, or congestive heart failure.,Hypertension (moderate to severe).,Hyperthyroidism.,Glaucoma.,History of drug abuse or alcoholism.,Concurrent use of monoamine oxidase inhibitors or within 14 days of such use.,Pregnancy and breastfeeding.,Agitated states.,History of seizure disorders.
Avoid grapefruit and grapefruit juice (CYP3A4 inhibition increases idelalisib exposure). Take with food to reduce nausea and diarrhea.
Avoid high-fat meals as they may delay absorption of oral formulations. No specific food-drug interactions known; however, anticholinergic effects may be exacerbated by alcohol.
Pregnancy Category D. First trimester: Risk of fetal malformations including neural tube defects and craniofacial anomalies based on animal studies showing embryo-fetal toxicity and teratogenicity. Second and third trimesters: Risk of fetal hematologic toxicity (leukopenia, neutropenia) and potential growth restriction. Counsel women of childbearing age to use effective contraception during treatment and for 1 month after last dose.
BONTRIL is classified as FDA Pregnancy Category X. First trimester: high risk of major congenital malformations including neural tube defects, cardiovascular anomalies, and cleft palate. Second and third trimesters: risk of fetal growth restriction, oligohydramnios, and neonatal respiratory depression if used near term.
No human data on presence in breast milk; risk of serious adverse reactions in breastfed infants (immunosuppression, neutropenia). M/P ratio not determined. Advise not to breastfeed during treatment and for 1 week after last dose.
No data available on excretion into human breast milk. M/P ratio unknown. Due to potential for serious adverse effects in nursing infants, breastfeeding is contraindicated during BONTRIL therapy.
No dose adjustment studies in pregnant women. Due to increased volume of distribution and altered clearance in pregnancy, therapeutic drug monitoring is not established. Use minimum effective dose. If used during pregnancy, monitor for maternal neutropenia, infections, and adjust dose per standard ANC thresholds (hold if ANC < 500/mm³; resume at reduced dose when ANC > 1000/mm³).
No dose adjustment required for pregnancy. However, due to teratogenicity, BONTRIL should be discontinued before conception or as soon as pregnancy is diagnosed.
Monitor for hepatotoxicity (ALT/AST elevations), severe cutaneous reactions (Stevens-Johnson syndrome), and pneumonitis. Requires hepatic function monitoring every 2 weeks for first 2 months, then monthly. Contraindicated with CYP3A4 inducers or strong inhibitors due to metabolism via CYP3A4. Dose reduction needed for moderate hepatic impairment (Child-Pugh B).
BONTRIL (hyoscyamine) is an anticholinergic used for GI spasms; avoid in patients with glaucoma, myasthenia gravis, or obstructive uropathy. Onset of action is 2-3 minutes IV; monitor for heat stroke in high ambient temperatures due to decreased sweating.
Take with food to reduce gastrointestinal side effects.,Avoid grapefruit and grapefruit juice during treatment.,Report any signs of liver problems (jaundice, dark urine, abdominal pain) or skin reactions (rash, blisters) immediately.,Use effective contraception during and for at least 1 month after treatment.,Do not stop or change dose without consulting your healthcare provider.
Do not drive or operate machinery until you know how this medication affects you, as it may cause dizziness or blurred vision.,Avoid alcohol and other CNS depressants as they may increase sedation.,Report immediately if you experience eye pain, difficulty urinating, or rapid heartbeat.,Use caution in hot weather; this drug reduces sweating and increases risk of heat stroke.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ZYDELIG vs BONTRIL, answered by our medical review team.
ZYDELIG is a PI3K Inhibitor Antineoplastic that works by Idelalisib is a selective inhibitor of phosphatidylinositol 3-kinase delta (PI3Kδ), blocking the PI3K/AKT signaling pathway, leading to reduced proliferation, survival, and migration of malignant B cells.. BONTRIL is a Sympathomimetic Anorectic that works by Bontril (phendimetrazine) is a sympathomimetic amine that acts as an appetite suppressant. Its mechanism involves stimulating the hypothalamus to release norepinephrine and dopamine, which reduces hunger cues. It is a prodrug that is metabolized to the active agent phenmetrazine, which inhibits reuptake and increases release of norepinephrine and dopamine in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ZYDELIG and BONTRIL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ZYDELIG is: 150 mg orally twice daily, taken with food.. The standard adult dose of BONTRIL is: BONTRIL 50 mg orally once daily, with or without food.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ZYDELIG and BONTRIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ZYDELIG is classified as Category C. Pregnancy Category D. First trimester: Risk of fetal malformations including neural tube defects and craniofacial anomalies based on animal studies showing embryo-fetal toxicity an. BONTRIL is classified as Category C. BONTRIL is classified as FDA Pregnancy Category X. First trimester: high risk of major congenital malformations including neural tube defects, cardiovascular anomalies, and cleft p. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.